Diabetes Clinical Trials in San Antonio, TX

52 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Phase 3	Eli Lilly and Company	<1 mi
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus	Phase 2	Ascletis Pharma (China) Co., Limited	<1 mi
Prevention of Progression of Prediabetes, Obesity and CV Risk	Phase 1	The University of Texas Health Science Center at San Antonio	<1 mi
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)	Phase 1/2	COUR Pharmaceutical Development Company, Inc.	<1 mi
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight	Phase 3	Eli Lilly and Company	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes	Phase 3	Eli Lilly and Company	<1 mi
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy	Phase 2	Boehringer Ingelheim	<1 mi
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma	Phase 2	Children's Oncology Group	<1 mi
Transformative Research in Diabetic Nephropathy	—	University of Pennsylvania	<1 mi
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist	Phase 2	AstraZeneca	<1 mi
SGLTi, Hepatic Glucose Production and Ketogenesis	Phase 1	The University of Texas Health Science Center at San Antonio	<1 mi
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes	Phase 3	Novo Nordisk A/S	<1 mi
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes	Phase 2	Zucara Therapeutics Inc.	<1 mi
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	Phase 3	Boehringer Ingelheim	<1 mi
Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers	N/A	LifeNet Health	<1 mi
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia	Phase 1	The University of Texas Health Science Center at San Antonio	<1 mi
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)	Phase 1	Gilead Sciences	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes	Phase 3	Eli Lilly and Company	<1 mi
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease	Phase 3	Prokidney	<1 mi
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)	—	Jaeb Center for Health Research	<1 mi
SGLT2i, Hepatic Glucose Production, and SNS	Early 1	The University of Texas Health Science Center at San Antonio	<1 mi
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants	Phase 4	The University of Texas Health Science Center at San Antonio	<1 mi
Fenofibrate for Prevention of DR Worsening	Phase 3	Jaeb Center for Health Research	<1 mi
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes	Phase 3	Kailera	<1 mi
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)	N/A	The University of Texas Health Science Center at San Antonio	<1 mi
SGLT2i, Pioglitazone, and Ketone Production in T2D	Phase 1	The University of Texas Health Science Center at San Antonio	<1 mi
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort	Phase 1	AstraZeneca	<1 mi
Dapagliflozin Plus Pioglitazone in T1DM	Phase 4	The University of Texas Health Science Center at San Antonio	<1 mi
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease	Phase 2	Novo Nordisk A/S	<1 mi
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes	Phase 3	The University of Texas Health Science Center at San Antonio	<1 mi
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes	N/A	Endogenex, Inc.	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin	Phase 3	Eli Lilly and Company	<1 mi
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes	Phase 3	vTv Therapeutics	<1 mi
Mirragen Diabetic Foot Ulcer Study	—	The University of Texas Health Science Center at San Antonio	<1 mi
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)	Phase 1	Merck Sharp & Dohme LLC	<1 mi
Bionic Pancreas in CFRD	Phase 3	Jaeb Center for Health Research	<1 mi
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)	Phase 3	Viking Therapeutics, Inc.	<1 mi
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus	Phase 2	Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	<1 mi
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes	Phase 4	Marzieh Salehi	<1 mi
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes	Phase 1	Eli Lilly and Company	<1 mi
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan	Early 1	The University of Texas Health Science Center at San Antonio	<1 mi
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes	Early 1	The University of Texas Health Science Center at San Antonio	<1 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	<1 mi
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/2	Aulos Bioscience, Inc.	<1 mi
Quantifying Hepatic Mitochondrial Fluxes in Humans	Phase 4	The University of Texas Health Science Center at San Antonio	<1 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	Phase 3	Eli Lilly and Company	12 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	Phase 3	Eli Lilly and Company	12 mi
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin	Phase 2	Eli Lilly and Company	12 mi
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes	Phase 3	Eli Lilly and Company	12 mi
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	Phase 2	Eli Lilly and Company	12 mi
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	Phase 2	Eli Lilly and Company	12 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	N/A	Cleerly, Inc.	46 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.